Experienced in Pancreatic Cancer

Dr. Kathryn A. Bylow

Hematology Oncology | Geriatrics | Hematology
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
Accepting New Patients
Offers Telehealth
Experienced in Pancreatic Cancer
The Medical College Of Wisconsin Inc
8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kathryn Bylow is a Hematologist Oncology specialist and a Geriatrics provider in Milwaukee, Wisconsin. Dr. Bylow is rated as an Experienced provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Liver Embolization, and Gastrostomy. Dr. Bylow is currently accepting new patients.

Her clinical research consists of co-authoring 11 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Pancreatic Cancer.

Specialties
Hematology Oncology
Geriatrics
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

THE MEDICAL COLLEGE OF WISCONSIN INC
8701 Watertown Plank Rd, Room 4041 Mfrc, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: September 22, 2023
Intervention Type: Other, Drug
Study Drugs: Standard of care ADT, HMB, Arginine, Glutamine
Study Phase: Phase 2
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

11 Total Publications

Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 23, 2025
Similar Doctors
Elite in Pancreatic Cancer
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology
Elite in Pancreatic Cancer
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.1 miles away)
414-805-3666
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Ben George is an Oncologist and a Hematologist Oncology provider in Milwaukee, Wisconsin. Dr. George is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreatectomy, and Endoscopy. Dr. George is currently accepting new patients.

Elite in Pancreatic Cancer
Dr. Paul S. Ritch
Oncology | Hematology
Elite in Pancreatic Cancer
Dr. Paul S. Ritch
Oncology | Hematology
9200 W Wisconsin Ave, Division Of Neoplastic Diseases, 
Milwaukee, WI 
 (0.2 miles away)
414-805-6800
Languages Spoken:
English
See accepted insurances

Paul Ritch is an Oncologist and a Hematologist in Milwaukee, Wisconsin. Dr. Ritch is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatectomy.

Elite in Pancreatic Cancer
Dr. Mandana Kamgar
Hematology Oncology | Hematology | Oncology
Elite in Pancreatic Cancer
Dr. Mandana Kamgar
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.1 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mandana Kamgar is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Kamgar is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. Her top areas of expertise are Pancreatic Cancer, Ampullary Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, and Pancreatectomy. Dr. Kamgar is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bylow's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile